NEW YORK, NY / ACCESSWIRE / June 26, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Beazer Homes USA, Inc. (“Beazer Homes” or the “Company”) (NYSE:BZH) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Beazer Homes stock or options between August 1, 2014 and May 2, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/BZH. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Beazer Homes securities between August 1, 2014 and May 2, 2019 (the “Class Period”). The case, Strougo v. Beazer Homes USA, Inc. et al., No. 19-cv-05301 was filed on June 5, 2019.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Beazer Homes’ California assets classified as land held for future development were deteriorating in value or improperly valuated; (2) the foregoing created a foreseeable risk of an eventual substantial impairment that would negatively impact the profitability of the Company; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On May 2, 2019, Beazer Homes issued a press release announcing its financial and

operating results for the second quarter of 2019. Among other issues, Beazer Homes announced a net loss from continuing operations of $100.8 million for the quarter, reflecting a $147.6 million impairment on certain California assets the Company had acquired before 2007. According to Defendants, all of the assets at issue were either currently or previously classified as land held for future development.

On this news, Beazer’s stock price fell from $14.24 per share on May 2, 2019 to $12.51 per share on May 3, 2019: a $1.73 or 12.15% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Beazer Homes’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 553529

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Cadence Bancorporation (“Cadence” or the “Company”) (NYSE: CADE). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Cadence and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 22, 2019, Cadence announced that the Company’s financial and operating results for the second quarter of 2019 were “negatively impacted by higher credit costs including net charge-offs of $18.6 million and loan provisions of $28.9 million,” which caused Cadence to miss second quarter earnings expectations.

On this news, Cadence’s stock price fell $3.75 per share, or 19.12%, to close at $15.86 per share on July 22, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 553674

CEDARHURST, NY / ACCESSWIRE / July 26, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Sunlands Technology Group (NYSE: STG)

Investors Affected : shareholders of Sunlands Technology Group who purchased shares pursuant and/or traceable to Sunlands’ March 2018 initial public stock offering.

A class action has commenced on behalf of certain shareholders in Sunlands Technology Group. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sunlands’ student enrollment was declining; (2) Sunlands’ gross billings were declining; (3) Sunlands’ marketing tactics were not as robust as described in the Registration Statement; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/sunlands-technology-group-loss-submission-form/?id=2637&from=1

Omnicell, Inc. (NASDAQGS: OMCL)

Investors Affected : October 25, 2018 – July 11, 2019

A class action has commenced on behalf of certain shareholders in Omnicell, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/omnicell-inc-loss-submission-form/?id=2637&from=1

Eagle Bancorp, Inc. (NASDAQCM: EGBN)

Investors Affected : March 2, 2015 – July 17, 2019

A class action has commenced on behalf of certain shareholders in Eagle Bancorp, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/eagle-bancorp-inc-loss-submission-form/?id=2637&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC

ReleaseID: 553675

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Netflix, Inc. (“Netflix” or the “Company”) (NASDAQ: NFLX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Netflix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 17, 2019, post-market, Netflix released a letter to shareholders which revealed that Netflix missed its expected target for number of new subscribers and lost 126,000 subscribers in the United States during the second quarter of 2019. Also on July 17, 2019, Netflix held an earnings call to discuss its financial and operating results for the quarter. During the earnings call, the Company’s Chief Financial Officer attributed the missed subscription target to the “timing of [Netflix’s] content slate” and price increases.

On this news, Netflix’s stock price fell $47.34 per share, or over 13%, over the following two trading sessions, closing at $315.10 per share on July 19, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 553670

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Karyopharm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 22, 2019, in advance of a U.S. Food and Drug Administration (“FDA”) advisory committee meeting to review Karyopharm’s New Drug Application (“NDA”) for selinexor and assess the drug’s risks and benefits, the FDA released a briefing document expressing serious concerns about the safety and efficacy of selinexor (the “FDA Report”). Significantly, the FDA Report revealed that, contrary to Karyopharm’s assurances, the Company’s previously canceled Phase 2 SOPRA trial had resulted in “worse overall survival” for acute myeloid leukemia (“AML”) patients treated with selinexor, which “highlight[ed] the toxicity of this drug.” The FDA also determined that the toxicity observed with selinexor in AML patients in the SOPRA study was “similar” to that observed in multiple myeloma patients in the Phase 2b STORM study. The FDA unambiguously concluded that “[t]reatment with selinexor is associated with significant toxicity” and has “limited efficacy.” On this news, Karyopharm’s stock price fell $3.90 per share, or 43.48%, to close at $5.07 per share on February 22, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 553672

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Bloom Energy Corporation (NYSE: BE)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/bloom-energy-corporation-loss-submission-form?prid=2636&wire=1
Lead Plaintiff Deadline: July 29, 2019
Class Period: on behalf of all persons who purchased or otherwise acquired Bloom Energy common stock pursuant or traceable to Bloom Energy’s July 2018 IPO.

The complaint alleges that Bloom Energy’s Registration Statement was materially misleading as it failed to disclose known events and trends that were severely affecting the Company’s business and that made investment in Bloom Energy significantly riskier than presented in the Registration Statement. In particular, the Registration Statement failed to disclose that the Company was experiencing material construction delays. These construction delays would cause system deployments (or “acceptances” as Defendants referred to them) to fall significantly below even the low end of the Company’s previously announced guidance.

While the Registration Statement purported to warn of risks that “may arise,” which could materially affect the Company, in actuality these material negative events were already occurring. As a result, the representations and purported risk disclosures were false and misleading because, by the time of the IPO, construction delays had already impacted or would soon impact Bloom Energy’s ability to deliver acceptances in line with its guidance.

Ra Medical Systems, Inc. (NYSE: RMED)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ra-medical-systems-inc-loss-submission-form?prid=2636&wire=1
Lead Plaintiff Deadline: August 6, 2019
Class Period: stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.

Allegations against RMED include that: (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Netflix, Inc. (NASDAQGS: NFLX)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/netflix-inc-loss-submission-form?prid=2636&wire=1
Lead Plaintiff Deadline: September 20, 2019
Class Period: April 17, 2019 to July 17, 2019

Allegations against NFLX include that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 553673

NEW YORK, NY / ACCESSWIRE / July 26, 2019 / Pomerantz LLP is investigating claims on behalf of investors of L Brands, Inc. (“L Brands” or the “Company”) (NYSE: LB). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether L Brands and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On November 19, 2018, L Brands issued a press release announcing its financial and operating results for the third quarter of 2018. The press release announced that L Brands intended to reduce its annual ordinary dividend to $1.20 from $2.40 beginning with the quarterly dividend to be paid in March 2019 in order to deleverage Company’s balance sheet over time.

On this news, L Brands’ stock price fell $6.12 per share, or approximately 17.7%, to close at $28.43 per share on November 20, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 553671

LOS ANGELES, CA / ACCESSWIRE / July 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sealed Air Corporation (“Sealed Air” or “the Company”) (NYSE: SEE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sealed Air announced after the market closed on June 20, 2019, that the Company had fired CFO Bill Stiehl. The firing comes following the audit committee’s completion of an internal review after the Company received an SEC subpoena. According to Sealed Air, the subpoena is for information on the selection of the Company’s independent audit firm along with the actual independence of that firm. Based on this news, shares of Sealed Air traded down significantly on June 21, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 553666

Premier Pharmacy Services can Supply Patients Access to this Aquaretic for the Treatment of Hyponatremia

BALDWIN PARK, CA / ACCESSWIRE / July 26, 2019 / Since 2015, Premier Pharmacy Services has been part of a pharmacy network, designed by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute SAMSCA® (tolvaptan). This medication is used to treat patients diagnosed with hyponatremia – a condition characterized by excessively low sodium levels in the blood. Premier Pharmacy Services is part of a limited network of pharmacies providing nationwide access to this medication.

Hyponatremia occurs in the United States in approximately 3-6 million people. Hyponatremia is a condition in which there is an excess of body water relative to body sodium (Defined as serum sodium concentration < 135 mEq/L). Hyponatremia is categorized into three main categories; hypervolemic, euvolemic, and hypovolemic.

SAMSCA® (tolvaptan) is the first-and-only oral vasopressin V2-receptor antagonist that increases serum sodium concentration through free water clearance. SAMSCA® (tolvaptan) is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with Syndrome of Inappropriate Antidiuretic Hormone (SIADH), heart failure, and cirrhosis. In healthy subjects, after a single 60 mg dose of SAMSCA®, free water clearance and serum sodium increase occurred within 2 to 4 hours post-dose.

“We are ecstatic to offer SAMSCA® as an extraordinary treatment to patients impacted by hyponatremia” said Stephen Samuel, CEO at Premier Pharmacy Services. “With our outstanding patient-focused customer service team, Premier Pharmacy Services works diligently to ensure our patients receive advanced therapy solutions while taking pride in our timely and expedited deliveries.”

About Premier Pharmacy Services

Premier Pharmacy Services is quad-accredited and headquartered in California with locations in Arizona, Missouri, Pennsylvania, and New Jersey. Premier Pharmacy Services’ mission is to promote optimal outcomes for persons enduring debilitating diseases while delivering industry-leading patient care with integrity, compassion, and excellence. Premier Pharmacy Services works around-the-clock to provide patient-centric support and care, while implementing a management model that guarantees the best possible outcome for life-altering therapies and treatments.

Premier Pharmacy Services – Your Premier Pharmacy in Southern California: https://www.premierpharmacyservices.com

Specialty Pharmacy Network for SAMSCA® (tolvaptan): https://www.samsca.com/sites/g/files/qhldwo1006/files/201809/Specialty%20Pharmacy%20Prescription%20Referral%20Template%20-%20PDF.pdf

Specialty Pharmacy – Premier Pharmacy Services: https://www.premierpharmacyservices.com/specialty-pharmacy.php

Contact Information:

Premier Pharmacy Services
Andrew Hogenson
VP Pharmacy Operations
626-626-9426
andrew@premierpharmacy.com
http://premierpharmacyservices.com/

SOURCE: Premier Pharmacy Services

ReleaseID: 553668